Paysign, Inc. (PAYS) - Q1 2025 10-Q Summary
Business Context and Reporting Period
Paysign, Inc. is a vertically integrated provider of prepaid card products, patient affordability offerings, and payment processing services. This report covers the quarterly period ended March 31, 2025. The company operates as a single reporting segment and is classified as a non-accelerated filer and smaller reporting company.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Total Revenues | $18,598,149 | $13,190,074 |
| Gross Profit | $11,690,828 | $6,939,251 |
| Gross Margin | 62.9% | 52.6% |
| Net Income | $2,586,100 | $309,096 |
| Diluted EPS | $0.05 | $0.01 |
| Operating Cash Flow | ($6,033,177) | $8,244,499 |
| Cash & Restricted Cash | $111,490,368 | $115,322,431 |
| Total Assets | $205,118,026 | $179,028,197 |
| Total Liabilities | $165,843,762 | $148,586,565 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 41.0% year-over-year. This was driven by a 260.8% surge in Pharma industry revenue ($8.62M vs $2.39M), offset by a 9.2% decline in Plasma industry revenue ($9.41M vs $10.37M) due to normalized inventory levels.
- Profitability: Net income increased 736.7% to $2.59M. Operating income turned positive at $2.49M compared to a loss of $258k in the prior year.
- Acquisition Activity: On March 19, 2025, Paysign acquired Gamma Innovation LLC for a total preliminary consideration of $17.76M (cash, equity, and earn-out). This resulted in $5.51M of new goodwill and $12.25M in identifiable intangible assets.
- Cash Flow Dynamics: Operating cash flow turned negative ($6.03M outflow) compared to a positive $8.24M in Q1 2024. This was primarily due to a $19.6M increase in accounts receivable and a $7.0M decrease in customer card funding liabilities, reflecting timing differences in pharma program invoicing and payments.
- Balance Sheet: Accounts receivable increased significantly to $52.2M (from $32.6M), while restricted cash decreased to $104.6M (from $111.6M).
Guidance, Outlook, and Risks
- Liquidity Outlook: Management believes available cash ($6.85M unrestricted) and forecasted cash flows are sufficient to sustain operations for the next 24 months.
- Strategic Focus: The company plans to continue investing in technology, sales, and marketing. Following the Gamma acquisition, marketing efforts are shifting to include donor engagement and resource management solutions.
- Legal Proceedings:
- Securities Class Action: A settlement of $3.75M (fully covered by D&O insurance) was approved by the court in April 2024.
- Derivative Actions: Four pending stockholder derivative actions have reached a proposed settlement in principle as of October 2024; preliminary approval is pending as of May 2025.
- Risk Factors: Concentration of credit risk exists with one financial institution holding deposits exceeding FDIC limits (though mitigated by deposit swapping). Additionally, one pharma customer represented 18% of accounts receivable as of March 31, 2025.
Investor Verification Checklist
- Verify the final valuation and earn-out terms of the Gamma Innovation LLC acquisition, as provisional amounts were used in this filing.
- Monitor the collection of the $52.2M accounts receivable balance, noting the concentration risk with a single pharma customer.
- Track the status of the pending preliminary approval for the stockholder derivative settlement.
- Assess the sustainability of the negative operating cash flow trend in the context of pharma program growth and receivables timing.
- Confirm the company's ability to fund future operations without raising new capital, as stated in management's liquidity assessment.